Akari Therapeutics, Plc announced on September 17, 2025, the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO). This application covers the company’s antibody drug conjugate (ADC) platform using Akari’s spliceosome payload PH1 for treating cancer by modulating alternative splicing within cancer cells.
This new patent application represents a new patent family, further extending Akari’s proprietary position regarding its novel PH1 payload, which is a novel Thailanstatin analog. The application details how PH1 modulates the spliceosome to disrupt alternative splicing drivers and the synthesis of proteins essential for cancer tumor survival and growth.
Abizer Gaslightwala, President and CEO of Akari, stated that these novel data demonstrate advances in understanding spliceosome modulation and the growing potential of the PH1 payload to build first-in-class ADCs. Disrupting alternative splicing is a fundamental approach to target a wide range of cancers, including those driven by specific spliced variants or other known factors.
This filing adds to the existing body of knowledge around the PH1 payload, which includes its potent cytotoxicity and robust immune cell activation demonstrated in multiple preclinical cancer models. The company is committed to applying this expanded knowledge to advance its current ADC portfolio, including AKTX-101 and future programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.